TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With IL28B Genotype by Cirrhosis Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean FibroScan Values by IL28B Genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: 58-week Retention Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUClast) of solifenacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of solifenacin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUClast) of tamsulosin HCl in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of tamsulosin HCl in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of the Ductus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Peak mitral valve mean gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak systolic pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in mitral valve regurgitation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Hemoglobin Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ability to achieve and maintain systolic blood pressure goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with symptomatic intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of whole body MRI in identifying distant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events compared to placebo
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in the weekly average of daily average pain intensity (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in drinking habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Posturographic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to achieve full feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete clearance of mf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: motor response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Death or First Thromboembolic Event (DTE)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Troponin I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum concentration (Cmax) of estetrol in plasma after single dose regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve from time 0 to 72 hours (AUC0-72h) of estetrol after single dose regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse events as a measure of safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Functional Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bioavailability of drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Key biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atorvastatin Apparent Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Volume of Distribution of the Central Compartment (Vc/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: SGPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Causality of adverse events to vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of patients showing T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of MRI sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With PCR-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early and sensitive diagnosis of Sanfilippo Type A-B-C-D disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative maximum AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative maximum ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom relief within the first 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure at day 7 (± 3 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of sarcoma to chemotherapy as determined by MRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: local and systemic recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Rates of Genetic Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of children requiring rescue medication
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in serum Folate Receptor (FR) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility of serum FR to distinguish between benign masses and malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of serum soluble FR as a marker for earlier detection of recurrent disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to maintain cells in culture or 3D matrices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meters walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Final Dose (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychiatric status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-free survival rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Hemodialysis (HD) patients that are eligible for the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible patients who agree to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of enrolled participants who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in microarchitecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scores on the UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State loneliness (numeric rating scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on the World Health Organization (WHO) Five Well-Being Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change on gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probe cocktail drugs concentration-time profile in plasma before LRYGB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probe cocktail drugs concentration-time profile in plasma 1 year after LRYGB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Perception in Quiet (Monosyllables)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of bacterial exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: lung function parameters (Δ FEV1, Δ FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LDL Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Psoriasis area severity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: FDG-PET/CT-scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with serious adverse drug reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: WOMAC Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change (Δ) in Accuracy of Time Interval Discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change (Δ) in Accuracy of N-back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change (Δ) in Reaction Time (RT) of N-back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change (Δ) in Symptoms (Depressed Mood)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change (Δ) in Symptoms (Anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Favorable Outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence rate of serious adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Range of Motion (ROM) of the Glenohumeral Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED95 equivalent dose of neuromuscular blocking agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose of reversal agents (neostigmine and/or sugammadex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpCO optimal threshold value for detection of CO poisoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of HPV DNA in esophagus biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for aortic valve replacement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Nutrition Habits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Physical Activity Habits
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Seroprotected Subjects Against Diphtheria and Tetanus Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With a Vaccine Response to Pertussis Toxoid, Filamentous Haemagglutinin and Pertactin Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Blood Pressure <140/85 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: presurgical psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Symptoms Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Tumor Response (OTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Irritability as measured by Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreas allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Wang Respiratory Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in larger middle molecule induced symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric and isokinetic peak torques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in patient's assessment of their personal contralateral breast cancer risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient's propensity to choose bilateral mastectomy
Endpoint domain: Life impact
Endpoint subdomain: Decision-making
Primary endpoint: Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Chemotherapy-Induced Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disturbance magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of hepatic carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: incidence rate of liver cirrhosis
Endpoint domain: Mortality/survival
Primary endpoint: incidence rate of fulminant hepatitis
Endpoint domain: Mortality/survival
Primary endpoint: AUCinf of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline CES-D score at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline BEPSI-K score at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: non-HDL lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long term safety (Follow-up for any AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary transforming growth factor-beta1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pelvic bone alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety-State (STAI-Y) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abnormal vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of Function (OKS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Grade 3 or Greater Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Renal function at 6 months post-transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gestational age (GA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of any of the 5 clinical risks (IUFD, neonatal death, respiratory morbidity, GI morbidity, and sepsis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time above 5 Minimum Inhibitory Concentration (T>5*MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum effective dose (presence/absence of visible MRI thalamotomy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in social communication symptoms
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mechanical detection threshold (grams)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic mechanical allodynia (numerical pain intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain pressure threshold (Newtons)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HCC or decompensated cirrhosis
Endpoint domain: Mortality/survival
Primary endpoint: Bronchoscopist satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under curve of verbal rating score (VRS) of pain moving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Hepatic Steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of children enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in N-Back Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in N-Back Correct Response Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression-free Survival at Week 52
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Severity Rating (CSR) of Targeted Specific Phobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential miRNA expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiplex Cytokine assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood mRNA expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SADE-free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing process of scleroderma digital ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Delay Discounting (DD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nuchal cord entanglement incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Presence and grade of obstructive sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Epworth Sleepiness Scale for Children and Adolescents (ESS(CHAD))
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Urinary Bisphenol A Level (BPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: muscular function state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the score of the CVI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of each CVI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Assessment through the adverse events reports
Endpoint domain: Adverse events/effects
Primary endpoint: Difficult Airway Criteria (through Arne Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intubation process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Breathing Comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Health Assessment Questionnaire (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of Prexasertib
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Dose Limiting Toxicity (DLT) to Prexasertib
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Time Curve for Prexasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Clinical Respiratory Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Estimated Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reliability of Severe Respiratory Insufficiency Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean difference in Apgar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in concentration of volatile organic compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline timed up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of sorafenib and RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes